NCT01303965 · REGISTRY CONDITION SEARCH

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1, PHASE2
Status at capture: TERMINATED
Registry last update: 2019-01-08

One of the complications that can occur after a stem cell transplant is called graft versus host disease (GVHD). Another complication is that multiple myeloma may come back (relapse). In this study, a drug called lenalidomide will be started 1-2 months after a transplant, or possibly later depending on recovery of your side effects. Lenalidomide and sirolimus have been shown to work together against multiple myeloma. Therefore, lenalidomide will be combined with sirolimus with the hope that this will help prolong the amount of time the disease is in remission. Researchers hope these steps will help prolong the amount of time the multiple myeloma is in remission and will decrease the chance of GvHD.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Phase I: Number of Participants With Dose Limiting Toxicity

→

outcome · POSTED

Phase II: Percent of Patients Alive and Free of Progression at 12 Months Following Transplant

→

outcome · POSTED

Phase II - Percent of Patients With Acute Graft Versus Host Disease (GvHD)

→

outcome · POSTED

Phase II - Percent of Patients With Chronic Graft Versus Host Disease (GvHD)

→

outcome · POSTED

Phase II - Percent of Patients With Treatment-related Deaths at 100 Days

→

outcome · POSTED

Phase II - Percent of Patients With Treatment-related Deaths at 1 Year

→

outcome · POSTED

Phase II - Time to Neutrophil Engraftment

→

outcome · POSTED

Phase II - Time to Platelet Engraftment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Recipient Inclusion Criteria: * 1\. Understand and voluntarily sign an informed consent form. * 2\. Age 18-70 years at the time of signing the informed consent form. * 3\. Able to adhere to the study visit schedule and other protocol requirements. * 4\. Previously documented multiple myeloma (MM) with measurable monoclonal protein by either serum/urine protein electrophoresis or serum free light chains, or measurable plasmacytomas. * 5\. ECOG performance status of 0-2 at study entry (see Appendix 2). * 6\. Acceptable organ function as outlined in the protocol. * 7\. Otherwise fitting institutional criteria for allogeneic stem cell transplantation. * 8\. Presence of an HLA-matched (5/6 or 6/6 matched for HLA-A, B, and DR) sibling donor, or a HLA-matched (matched for at least HLA-A, B, C, and DRB1) unrelated donor by high-resolution testing. * 9\. Disease free of prior malignancies for \>/= 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "insitu" of the cervix or breast. * 10\. All study participants must be registered into the mandatory RevAssist® program, and be willing and able to comply with the requirements of RevAssist®. * 11\. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test Recipient Exclusion Criteria: * 1\. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. * 2\. Pregnant or breast feeding females. * 3\. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * 4\. Known hypersensitivity to thalidomide or Lenalidomide. * 5\. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. * 6\. Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine or prior infection to which they are now immune (i.e., not carriers) are eligible. Donor Inclusion Criteria: The following categories of donor will be acceptable: * 1\. HLA-matched related donor (5/6 or 6/6 match): Minimal typing necessary is serologic typing for class I (A, B) and molecular typing for class II (DRB1). * 2\. HLA-matched Unrelated Donor (MUD): Molecular identity at least at HLA A, B, C, and DRB1 and DQB1 (8/10 match) by high resolution typing is required. * 3\. Syngeneic donors are not eligible. * 4\. The donor must be healthy and must be an acceptable donor as per institutional standards for marrow or stem cell donation. * 5\. Age ≥ 18 years
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Use sirolimus and tacrolimus as GvHD prophylaxis with sirolimus and lenalidomide as post-transplant maintenance
intervention Names
Drug: Sirolimus
Drug: Tacrolimus
Drug: Lenalidomide
label
Open Label, Single Arm
type
EXPERIMENTAL

interventions

arm Group Labels
Open Label, Single Arm
description
Start on Day -3 and continue for 1 year
name
Sirolimus
type
DRUG
arm Group Labels
Open Label, Single Arm
description
Start on Day -3 and begin tapering on Day +100 until Day +180.
name
Tacrolimus
type
DRUG
arm Group Labels
Open Label, Single Arm
description
Start between Day +30 and +120 and continue for 1 year.
name
Lenalidomide
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 14
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
The number of patients who had a DLT during the dose finding/confirming portion (Phase I) of the trial for the safety of the combination of sirolimus, tacrolimus and lenalidomid. Patients will be monitored for 28 days (a cycle) to determine whether a DLT is experienced for the specific dose level.
measure
Phase I: Number of Participants With Dose Limiting Toxicity
time Frame
28 days
description
Percent of patients and the 95% Binomial Confidence interval who were alive and free of progression at 12 months following transplant for the patients in Phase II. Progression will be based on International Myeloma Working Group criteria where patients may meet any one of the following criteria - increase of 25% or more in serum or urine M-protein from baseline, Serum M-protein and/or the absolute increase must be \>=0.5 g/dl, Urine M-protein and/or absolute increase must be \>=200 mg/24 hours, development of new bone lesions or soft tissue plasmacyomas or definite increase in the size of existing bone lesions or soft tissue plasmacyomas, or development of hypercalcemia (corrected serum Ca++\>11.5 mg/dl) that can be attributed solely to plasma cell proliferative disease.
measure
Phase II: Percent of Patients Alive and Free of Progression at 12 Months Following Transplant
time Frame
Transplant (Day 0) through 1 year post-transplant

secondary Outcomes

description
Percent of patients and the 95% Binomial Confidence interval who had any stage I-IV acute GvHD based on the modified Keystone Grading Scale for skin, liver and gastrointestinal symptoms for patients in Phase II. Zero means no acute GvHD was reported, and higher stages are worse outcomes (range of 0-4). For skin: 0=no rash; 1=erthematous macular rash over \<25% body surface; 2=over 25-50% of body surface; 4=bullae, exfoliation ulcerative dermatitis. For liver (bilirubin (mg/dL)): 0= \<2.0; 1= 2-\<2.9; 3= 3-\<5.9; 4= \>=15 . For gut changes (diarrhea\[ml/day\]): 0=none; 1= \>500-1000; 2= \>1000-1500; 3= \>1500; 4=severe abdominal pain with or without ileus. Overall grade 0: Skin=0; liver=0; gut changes=0. Overall grade 1: Skin with 1 or 2; liver=0; gut changes=0. Overall grade 2: Skin with 1, 2, or 3; liver=1; gut changes=1. Overall grade 3: Skin with 2 or 3; liver with 2 or 3; gut changes with 2 or 3. Overall grade 4: Patients with grade 4 toxicity in any organ system.
measure
Phase II - Percent of Patients With Acute Graft Versus Host Disease (GvHD)
time Frame
Day 0 through 1 year post transplantation
description
Percent of patients and the 95% Binomial Confidence interval who had any chronic GvHD reported based on Filipovich et al. consensus document (BB\&MT 2005) and Akpek et al. chronic GvHD grading system (Blood 2003) for patients in Phase II.
measure
Phase II - Percent of Patients With Chronic Graft Versus Host Disease (GvHD)
time Frame
Transplant (Day 0) through 1 year post-transplant
description
Percent of patients and the 95% Binomial Confidence interval who had treatment-related deaths by 100 days for patients in Phase II.
measure
Phase II - Percent of Patients With Treatment-related Deaths at 100 Days
time Frame
100 days post transplant
description
Percent of patients and the 95% Binomial Confidence interval who had treatment-related deaths by 1 year for patients in Phase II.
measure
Phase II - Percent of Patients With Treatment-related Deaths at 1 Year
time Frame
Transplant (Day 0) through 1 year post-transplant
description
Time to neutrophil engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of neutrophils is defined as the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l. Patients surviving at least 14 days after transplant will be evaluable for this endpoint. Patients who did not have neutrophil engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided.
measure
Phase II - Time to Neutrophil Engraftment
time Frame
Transplant (Day 0) through 1 year post transplant
description
Time to platelet engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of platelets is defined as the time from day 0 to the first of three consecutive Complete Blood Counts (CBCs) obtained on different days after transplantation during which the platelet count is at least 20 x109/l. The CBCs obtained should be at least seven days after the most recent platelet transfusion. Only patients who achieved engraftment of platelets will be included in the analysis. The median and 95% confidence intervals will be provided.
measure
Phase II - Time to Platelet Engraftment
time Frame
Transplant (Day 0) through 1 year post-transplant

Full study description

brief Summary: One of the complications that can occur after a stem cell transplant is called graft versus host disease (GVHD). Another complication is that multiple myeloma may come back (relapse). In this study, a drug called lenalidomide will be started 1-2 months after a transplant, or possibly later depending on recovery of your side effects. Lenalidomide and sirolimus have been shown to work together against multiple myeloma. Therefore, lenalidomide will be combined with sirolimus with the hope that this will help prolong the amount of time the disease is in remission. Researchers hope these steps will help prolong the amount of time the multiple myeloma is in remission and will decrease the chance of GvHD.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-180854a7277a30603848
requested nct id
NCT01303965
primary nct id
NCT01303965
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
e01a8e8d0fe09907edd5880ff184db182936156e279a4a3e610b51be6ee0b80f
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-180854a7277a30603848
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01303965
occurrences
context exact
NCT01303965
end
11
exact text
NCT01303965
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/570/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
fa28624ac59fcd23a1bf6eff2f7b1a09274f1052f6ad6ac98ee2b78af015b036
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice